| Gregg A Horras, MD | |
|
1025 Marsh St, Mankato, MN 56001-4752 | |
| (507) 594-4863 | |
| Not Available |
| Full Name | Gregg A Horras |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 24 Years |
| Location | 1025 Marsh St, Mankato, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1811903842 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 43850-20 (Wisconsin) | Secondary |
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 49152 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sacred Heart Hospital | Eau claire, WI | Hospital |
| North Memorial Health | Robbinsdale, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sacred Heart Hospital Of The Hospital Sisters-3rd Order Of St Francis | 8729072418 | 122 |
| North Memorial Health Care | 0042123028 | 483 |
News Archive
The American Gastroenterological Association (AGA) is excited to announce the 17 researchers selected to receive funding through the AGA Research Foundation Awards Program.
Novartis announced today that Tafinlar (dabrafenib) + Mekinist (trametinib), the first oral combination therapy to be licensed for advanced melanoma, is now available in the UK for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Rigel Pharmaceuticals, Inc. has announced the presentation of clinical data for R112, the company's lead candidate for the treatment of allergic rhinitis, during a poster session at the annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Francisco, CA. The phase I/II single dose trial demonstrated that R112 was well tolerated and showed favorable biological effects.
Dementia-associated weight loss begins before the onset of the definite dementia symptoms and accelerates by the time of the diagnosis, according to a study in the January issue of Archives of Neurology.
› Verified 5 days ago
| Entity Name | County Of Milwaukee |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942362066 PECOS PAC ID: 0446162887 Enrollment ID: O20031104000139 |
News Archive
The American Gastroenterological Association (AGA) is excited to announce the 17 researchers selected to receive funding through the AGA Research Foundation Awards Program.
Novartis announced today that Tafinlar (dabrafenib) + Mekinist (trametinib), the first oral combination therapy to be licensed for advanced melanoma, is now available in the UK for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Rigel Pharmaceuticals, Inc. has announced the presentation of clinical data for R112, the company's lead candidate for the treatment of allergic rhinitis, during a poster session at the annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Francisco, CA. The phase I/II single dose trial demonstrated that R112 was well tolerated and showed favorable biological effects.
Dementia-associated weight loss begins before the onset of the definite dementia symptoms and accelerates by the time of the diagnosis, according to a study in the January issue of Archives of Neurology.
› Verified 5 days ago
| Entity Name | Sacred Heart Hospital Of The Hospital Sisters-3rd Order Of St Francis |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619355351 PECOS PAC ID: 8729072418 Enrollment ID: O20150814013380 |
News Archive
The American Gastroenterological Association (AGA) is excited to announce the 17 researchers selected to receive funding through the AGA Research Foundation Awards Program.
Novartis announced today that Tafinlar (dabrafenib) + Mekinist (trametinib), the first oral combination therapy to be licensed for advanced melanoma, is now available in the UK for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Rigel Pharmaceuticals, Inc. has announced the presentation of clinical data for R112, the company's lead candidate for the treatment of allergic rhinitis, during a poster session at the annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Francisco, CA. The phase I/II single dose trial demonstrated that R112 was well tolerated and showed favorable biological effects.
Dementia-associated weight loss begins before the onset of the definite dementia symptoms and accelerates by the time of the diagnosis, according to a study in the January issue of Archives of Neurology.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gregg A Horras, MD 1025 Marsh St, Mankato, MN 56001-4752 Ph: (507) 594-4863 | Gregg A Horras, MD 1025 Marsh St, Mankato, MN 56001-4752 Ph: (507) 594-4863 |
News Archive
The American Gastroenterological Association (AGA) is excited to announce the 17 researchers selected to receive funding through the AGA Research Foundation Awards Program.
Novartis announced today that Tafinlar (dabrafenib) + Mekinist (trametinib), the first oral combination therapy to be licensed for advanced melanoma, is now available in the UK for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Rigel Pharmaceuticals, Inc. has announced the presentation of clinical data for R112, the company's lead candidate for the treatment of allergic rhinitis, during a poster session at the annual meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Francisco, CA. The phase I/II single dose trial demonstrated that R112 was well tolerated and showed favorable biological effects.
Dementia-associated weight loss begins before the onset of the definite dementia symptoms and accelerates by the time of the diagnosis, according to a study in the January issue of Archives of Neurology.
› Verified 5 days ago
Edward C Sathoff, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1400 E Madison Ave, Ste 352 Mankato Clinic Dept Of Psychiatry, Mankato, MN 56001 Phone: 507-387-3195 | |
Kimberly A Aho, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1230 E Main St, Mankato, MN 56001 Phone: 507-625-1811 | |
Dr. Travis D. Hansen, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1400 Madison Ave, Suite352, Mankato, MN 56001 Phone: 507-625-1811 Fax: 507-625-3928 | |
Lisa R Davidson, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1230 E Main Street, Mankato Clinic At Main Street, Mankato, MN 56002 Phone: 507-625-1811 | |
Vyoma Acharya, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1025 Marsh St, Mankato, MN 56001 Phone: 507-625-4031 | |
Delmer Eggert, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 22 Bela Vista Ct, Mankato, MN 56001 Phone: 507-345-6662 | |
Robert J Olson, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1400 E Madison Ave, Suite 352, Mankato, MN 56001 Phone: 507-387-3195 |